

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

CW9019

RRID:CVCL_N820

Type: Cell Line

Proper Citation

RRID:CVCL_N820

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_N820

Proper Citation: RRID:CVCL_N820

Description: Cell line CW9019 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Sex unspecified

Disease: Alveolar rhabdomyosarcoma

Defining Citation: [PMID:19235922](#), [PMID:22142829](#), [PMID:23665679](#), [PMID:23882450](#)

Comments: From: Barr, Frederic G.; School of Medicine, University of Pennsylvania; Philadelphia; USA., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: CW9019

Synonyms: CW-9019

Cross References: cancercelllines:CVCL_N820, Cell_Model_Passport:SIDM01481, Cosmic:1718358, Cosmic:2356038, DepMap:ACH-001050, GEO:GSM219747, Wikidata:Q54817048

ID: CVCL_N820

Record Creation Time: 20220427T215606+0000

Record Last Update: 20260913T002601+0000

Ratings and Alerts

No rating or validation information has been found for CW9019.

No alerts have been found for CW9019.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. *Molecular cancer therapeutics*, 25(1), 156.

Rask GC, et al. (2025) Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. *Cancer research communications*, 5(9), 1584.